Research Study

A Phase 1 Trial to Evaluate the Potential Impact of Renal Impairment on the Pharmacokinetics and Safety of CPX-351 (Daunorubicin and Cytarabine) Liposome for Injection Treatment in Adult Patients With Hematologic Malignancies
Principal Investigator 
David Sanford

Overview

Body Locations and Systems 
Leukemia
ClinicalTrials.gov# 
NCT03555955
Status 
Recruiting
Study Start/End 
Nov 29, 2019 to Jan 31, 2021
Locations 
Vancouver General Hospital
Name/Title 
Hong Li, Research Coordinator
Phone 
604-875-4111 ext.52496
Email Address 
hong.li@bccancer.bc.ca
Purpose of Study 

The purpose of this study is to evaluate the pharmacokinetics and safety of CPX-351 in patients with acute myeloid leukemia with moderate or severe renal impairment.

Eligibility 

Visit ClinicalTrials.gov for more information.

Disclaimer 

Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific research studies only. If you have specific questions which require clinical expertise, please call your primary care physician.